Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
The Celiac Center at Beth Israel Deaconess Medical Center, Harvard Medical School, USA.
J Autoimmun. 2024 Feb;143:103170. doi: 10.1016/j.jaut.2024.103170. Epub 2024 Jan 28.
Celiac disease (CeD) has been linked to an increased risk of other autoimmune diseases, yet the impact of delayed CeD diagnosis on risk of developing additional autoimmune diseases remains uncertain. We investigated this through a nationwide matched case-control study.
Using the ESPRESSO cohort with histophatology data from Sweden's 28 pathology departments, we assessed 46,575 biopsy-confirmed CeD cases from 1964 to 2017. We extracted 225,295 matched controls without histopathology information from the Swedish Total Population Register. Autoimmune disease was defined through diagnostic codes in the National Patient Register. Through conditional logistic regression we estimated odds ratio (OR) of autoimmune disease up until CeD diagnosis/matching date comparing CeD cases to controls across different age strata.
A total of 3059 (6.6 %) CeD patients and 4076 (1.8 %) controls had earlier autoimmune disease. The overall OR for autoimmune disease in CeD was 3.50 (95%CI 3.32-3.70). The risk of autoimmune disease did not escalate with increasing age at CeD diagnosis. Compared with controls, the OR of autoimmune disease in CeD patients was 7.70 (95%CI 4.71-12.57) in those diagnosed with CeD in 0-4 years, 19.02 (95%CI 13.80-26.23) in 5-9 years, 6.18 (95%CI 5.14-7.44) in 10-14 years, 4.80 (95%CI 3.97-5.79) in 15-19 years, 4.24 (95%CI 3.55-5.07) in 20-29 years, 4.65 (95%CI 3.93-5.51) in 30-39 years, 3.67 (95%CI 3.30-4.09) in 40-59 years, and 1.67 (95%CI 1.50-1.85) in ≥60 years.
This study revealed an increased risk of autoimmune disease among CeD patients compared with controls. However, older age at CeD diagnosis did not seem to escalate the risk of autoimmune diseases.
乳糜泻(CeD)与其他自身免疫性疾病的风险增加有关,但延迟诊断 CeD 对发展其他自身免疫性疾病的风险的影响仍不确定。我们通过全国性的病例对照研究对此进行了调查。
利用 ESPRESSO 队列和来自瑞典 28 个病理部门的组织病理学数据,我们评估了 1964 年至 2017 年间经活检证实的 46575 例 CeD 病例。我们从瑞典总人口登记册中提取了 225295 名无组织病理学信息的匹配对照。自身免疫性疾病是通过国家患者登记册中的诊断代码定义的。通过条件逻辑回归,我们比较了不同年龄组的 CeD 病例和对照,估计了直到 CeD 诊断/匹配日期为止自身免疫性疾病的优势比(OR)。
共有 3059 例(6.6%)CeD 患者和 4076 例(1.8%)对照患有早期自身免疫性疾病。CeD 患者的总体自身免疫性疾病 OR 为 3.50(95%CI 3.32-3.70)。随着 CeD 诊断年龄的增加,自身免疫性疾病的风险并未增加。与对照组相比,在 0-4 岁、5-9 岁、10-14 岁、15-19 岁、20-29 岁、30-39 岁、40-59 岁和≥60 岁时诊断为 CeD 的患者中,自身免疫性疾病的 OR 分别为 7.70(95%CI 4.71-12.57)、19.02(95%CI 13.80-26.23)、6.18(95%CI 5.14-7.44)、4.80(95%CI 3.97-5.79)、4.24(95%CI 3.55-5.07)、4.65(95%CI 3.93-5.51)、3.67(95%CI 3.30-4.09)、1.67(95%CI 1.50-1.85)。
本研究显示,与对照组相比,CeD 患者发生自身免疫性疾病的风险增加。然而,CeD 诊断年龄较大似乎并未增加自身免疫性疾病的风险。